deferoxamine has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 6 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Effect of the iron chelator deferoxamine (DF) on the production of endogenous porphyrins was studied in adenocarcinoma WiDr cells and erythroid K562 cells in vitro." | 3.73 | Deferoxamine photosensitizes cancer cells in vitro. ( Juzenas, P; Juzeniene, A; Moan, J, 2005) |
| "A 4-year-old girl with juvenile chronic myeloid leukemia relapsed after an allogeneic bone marrow transplantation (BMT) and became refractory to conventional chemotherapy." | 1.27 | Deferoxamine (Desferal)-induced ocular toxicity. ( Bashara, S; Goshen, Y; Kaplinsky, C; Stark, B; Yaniv, I; Zaizov, R, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Franchini, M | 1 |
| Gandini, G | 1 |
| Veneri, D | 1 |
| Aprili, G | 1 |
| Juzenas, P | 1 |
| Juzeniene, A | 1 |
| Moan, J | 1 |
| Glickstein, H | 1 |
| Breuer, W | 1 |
| Loyevsky, M | 1 |
| Konijn, AM | 1 |
| Shanzer, A | 1 |
| Cabantchik, ZI | 1 |
| Tang, CK | 1 |
| Chin, J | 1 |
| Harford, JB | 1 |
| Klausner, RD | 1 |
| Rouault, TA | 1 |
| Dezza, L | 1 |
| Cazzola, M | 1 |
| Danova, M | 1 |
| Carlo-Stella, C | 1 |
| Bergamaschi, G | 1 |
| Brugnatelli, S | 1 |
| Invernizzi, R | 1 |
| Mazzini, G | 1 |
| Riccardi, A | 1 |
| Ascari, E | 1 |
| Kaplinsky, C | 1 |
| Stark, B | 1 |
| Goshen, Y | 1 |
| Yaniv, I | 1 |
| Bashara, S | 1 |
| Zaizov, R | 1 |
6 other studies available for deferoxamine and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: an update.
Topics: Aged; Anemia; Deferoxamine; Female; Humans; Injections, Subcutaneous; Iron Chelating Agents; Iron Ov | 2004 |
Deferoxamine photosensitizes cancer cells in vitro.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Survival; Deferoxamine; Dose-Response Relationship, Drug; Dos | 2005 |
Differential cytotoxicity of iron chelators on malaria-infected cells versus mammalian cells.
Topics: Animals; Antimalarials; Carcinoma, Hepatocellular; Cell Division; Chemical Phenomena; Chemistry, Phy | 1996 |
Iron regulates the activity of the iron-responsive element binding protein without changing its rate of synthesis or degradation.
Topics: Animals; Blotting, Western; Cell Line; Cloning, Molecular; Deferoxamine; Escherichia coli; Ferritins | 1992 |
Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies.
Topics: Anemia, Refractory, with Excess of Blasts; Blast Crisis; Cell Division; Colony-Forming Units Assay; | 1989 |
Deferoxamine (Desferal)-induced ocular toxicity.
Topics: Blindness; Child, Preschool; Deferoxamine; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL P | 1988 |